Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack
Salas-Benito D., Melero I., Ponz-Sarvise M.
Abstract No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes–based vaccine encoding for mesothelin in combination with a GM-CSF–transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients. See related article by Le et al., p. 5493